In Vivo Measurement of Vesicular Monoamine Transporter Type 2 Density in Parkinson Disease with <sup>18</sup>F-AV-133

2010135 citationsJournal Articlebronze Open Access

Authors

Nobuyuki Okamura · Austin Health

Victor L. Villemagne · University of Melbourne

John Drago · University of Melbourne

Svetlana Pejoska · Austin Health

Rajinder K. Dhamija · University of Melbourne

Rachel S. Mulligan · Austin Health

Julia R. Ellis ·

Abstract

These findings indicate that the novel (18)F-labeled ligand (18)F-AV-133 can sensitively detect monoaminergic terminal reductions in PD patients. Studies with (18)F-AV-133 may allow the presymptomatic identification of individuals with disorders characterized by degeneration of dopaminergic nigrostriatal afferents.

Topics & Keywords

Parkinson's Disease Mechanisms and Treatments Neurological disorders and treatments Neurotransmitter Receptor Influence on Behavior

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Nuclear Medicine

Volume 51, Issue 2, pp. 223-228

DOI: 10.2967/jnumed.109.070094

Field-Weighted Citation Impact: 7.95